What is the prevalence of Dupuytrens Contracture?

TL;DR: Dupuytren’s contracture is a common fibroproliferative disorder of the hand, with prevalence rates varying significantly by age and ethnicity, often reaching 10–20% in populations over age 60. While frequently labeled as a common condition in clinical practice, it is often underdiagnosed in early stages, leading to difficulty in establishing precise global incidence figures.

Is Dupuytren’s contracture considered a rare disease?

In many regions, Dupuytren’s contracture is not classified as a "rare" disease because it affects a significant portion of the aging population, particularly those of Northern European descent. Prevalence estimates vary widely; for example, some studies suggest that among men over the age of 65, the prevalence of Dupuytren’s contracture may be as high as 20–30%. However, because the condition often presents with mild symptoms—such as small nodules in the palm—many individuals do not seek medical attention, leading to significant underdiagnosis in epidemiological datasets.

How does age and gender impact prevalence?

The development of Dupuytren’s contracture is strongly correlated with advancing age. It is rare in pediatric populations and typically begins to manifest in middle age, with the average age of onset falling between 40 and 60 years. Regarding gender distribution, Dupuytren’s contracture shows a clear predilection for males, who are affected at a rate approximately 3 to 7 times higher than females. Furthermore, when the condition occurs in women, it often presents at a later age and may be less severe than in men.

Are there ethnic or geographic variations?

Research indicates that Dupuytren’s contracture has a distinct geographic and ethnic distribution. It is most frequently observed in individuals of Northern European, Scandinavian, and Celtic descent, earning it the historical moniker "the Viking disease." While Dupuytren’s contracture can occur in any ethnic group, it is significantly less common in populations of African or Asian descent. This suggests a strong genetic predisposition that interacts with environmental and lifestyle factors.

What factors complicate accurate data collection?

Accurately mapping the prevalence of Dupuytren’s contracture is challenging for several reasons:

• Asymptomatic progression: Many people have palmar nodules that never progress to a contracture, meaning they never enter the clinical record.


• Diagnostic criteria: Studies use different thresholds for diagnosis (e.g., presence of a nodule vs. presence of a finger flexion contracture), which makes comparing datasets difficult.


• Reporting bias: Because Dupuytren’s contracture is often managed in primary care or by hand specialists without being reported to central registries, true incidence rates are likely higher than reported.


• Community insights: At DiseaseMaps.org, 167 people with Dupuytren’s contracture have joined the community to share their experiences. This real-world patient data provides a vital complement to clinical studies by highlighting the lived impact of the condition, including secondary symptoms like shoulder pain and restricted mobility that are sometimes overlooked in standard clinical literature.

Next steps

• Consult a hand surgeon or a rheumatologist to assess the severity of your contracture and discuss options like needle aponeurotomy or collagenase injections.


• Keep a symptom diary to track the progression of your nodules and any changes in finger range of motion.


• Join the DiseaseMaps.org community to connect with others navigating the challenges of Dupuytren’s contracture.


• Discuss physical therapy with your doctor to manage the secondary shoulder and hand stiffness associated with the condition.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• OMIM (Online Mendelian Inheritance in Man): Dupuytren Contracture entry


• The Dupuytren Research Group